Biofusion Launches Absynth Biologics

Biofusion Launches Absynth Biologics to Focus on New Treatments for MRSA infection Biofusion plc ('Biofusion'), the university IP commercialisation company, today announces the launch of a new portfolio company, Absynth Biologics Ltd ('Absynth '), which will develop vaccines and antibodies to treat infections caused by the bacterium Staphylococcus aureus (S. aureus) including its more difficult-to-treat drug-resistant form, methicillin-resistant S. aureus (MRSA).

Biofusion has agreed to invest up to £325,000 in the Company to enable it to produce lead vaccine and therapeutic antibody candidates to begin the clinical trial process. Hospital acquired infections are an increasing public health concern and are responsible for a rise in the number of hospital deaths. These infections are caused by micro-organisms such as S. aureus and in particular its drug-resistant form, methicillin-resistant S. aureus (MRSA). Absynth's unique patented technology has been developed at the University of Sheffield and will be used to develop an MSRA vaccine and antibodies to treat significant MRSA related infections as well as other applications.